| Symbol | INNMF |
|---|---|
| Name | AMPLIA THERAPEUTICS LTD. |
| Sector | UNDEFINED |
| Region | Oceania |
| Industry | - |
| Address | 3000 Australia VA Level 17, 350 Queen Street |
| Telephone | +61 3 9123 1140 |
| Fax | — |
| — | |
| Website | https://www.ampliatx.com/site/content/ |
| Incorporation | AU |
| Incorporated On | 2016 |
| Employees | — |
| Fiscal Year | 3/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Grant Thornton Australia; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The companys product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. Additional info from OTC: |
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
Read moreAmplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
Read morePoster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
Read more